Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Vanda Profits Plummet on Royalty Drought

May 5, 2011 10:29 am | News | Comments

Vanda Pharmaceuticals Inc. said that its profit fell 74 percent in the first quarter as it booked sharply lower royalty revenue and no product sales. The company earned $136,000, or broke even on a per-share basis.

TOPICS:

Next-Generation Albumin Platform

May 5, 2011 10:20 am | Drug Discovery & Development | Product Releases | Comments

Built on Novozymes’ Albufuse platform, the Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.

TOPICS:

Navitar Acquiring Modulation Optics

May 5, 2011 10:12 am | News | Comments

Navitar Life Sciences, Inc., a leading optics manufacturer, announced they have entered into a binding agreement to acquire assets of Modulation Optics and their world?leading Hoffman Modulation Contrast Imaging Technology.

TOPICS:
Advertisement

Aceto Appoint New Board Member

May 5, 2011 10:04 am | News | Comments

Aceto Corporation, a leader in the pharmaceutical, nutraceutical, and specialty chemical spaces, announced that Salvatore Guccione has been elected to the company's Board of Directors.

TOPICS:

High-Throughput Screening Platform

May 5, 2011 9:59 am | Product Releases | Comments

Thermo Fisher Scientific Inc. and TTP LabTech have combined the Thermo Scientific RapidStak microplate mover and the TTP LabTech mosquito X1 nanoliter pipettor to provide high-speed plate handling and precision, low-volume sampling from high-density formats.

TOPICS:

Automated DNA Extraction

May 5, 2011 9:51 am | Product Releases | Comments

Greiner Bio-One will be unveiling the CheckExtractor at EUROGIN 2011, a congress focusing on human papillomaviruses (HPV) and illnesses caused by HPV, such as cervical cancer.

TOPICS:

Revatio Approved for Deadly Lung Disease in Children

May 5, 2011 9:45 am | News | Comments

Drugmaker Pfizer Inc. says the European commission has approved treating children with its medicine for a rare, deadly lung condition. The drug, Revatio, was approved in Europe about six years ago.

TOPICS:

Rexahn Continuing Enrollment of MDD Trial

May 5, 2011 9:35 am | News | Comments

Rexahn Pharmaceuticals, Inc. announced that it has enrolled two-thirds of the total patients needed for its Phase 2b clinical trial to study the safety and efficacy of Serdaxin to treat major depressive disorder.

TOPICS:
Advertisement

EU Approves Janssen's XEPLION

May 5, 2011 9:26 am | News | Comments

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, announced that the first injectable product using EDT’s NanoCrystal technology has been approved by the European Commission.

TOPICS:

EMA Monitoring Japanese Drugs for Radiation

May 5, 2011 9:21 am | News | Comments

The European Medicines Agency is working to monitor and evaluate the possible risk of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Daiichi nuclear power plant.

TOPICS:

Study Reveals TA-65 Behavior(2)

May 5, 2011 8:39 am | News | Comments

A study, “The Telomerase Activator TA-65 elongates short telomeres and increases healthspan of adult/old mice without increasing cancer incidence” describes TA-65’s mechanism of action and organismal response.

TOPICS:

Provectus Receives Orphan Drug Designation

May 5, 2011 8:33 am | News | Comments

Provectus Pharmaceuticals, Inc. received orphan drug designation by the U.S. Food and Drug Administration (FDA) for Rose Bengal, the active ingredient in oncology drug PV-10, for the treatment of hepatocellular carcinoma (HCC)– the most common form of liver cancer.

TOPICS:

Debiopharm, Aurigene Collaborate on Debio 1142

May 5, 2011 8:29 am | News | Comments

Debiopharm Group and Aurigene Discovery Technologies signed an agreement concerning the development and commercialization of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.

TOPICS:

Celldex Loss Widens on Revenue Dip

May 5, 2011 8:23 am | News | Comments

Cancer drug developer Celldex Therapeutics Inc. reported a larger first-quarter loss, saying its revenue and investment income decreased. Celldex lost $10.1 million, or 31 cents per share.

TOPICS:

Par Bottom Line Stung By $196M Settlement

May 5, 2011 8:19 am | News | Comments

Par Pharmaceutical posted a first-quarter loss following a quarter in which the generic drug developer saw sales of a key drug slide and also a hefty legal charge.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading